Jaguar Health announces Q2 results…targets MVID NDA submission in Q2 2027

JAGX Jaguar Health Inc

$5.62 +18.82%

View chart & analysis →

1. 1Jaguar Health (JAGX) announced its Q2 2026 consolidated results
2. 2Net product revenue from prescription drugs was approximately $1.2 million, down 60% from about $2.9 million in the year-ago period
3. 3The company remains focused on developing rare cholestasis therapy crofelemer and expects to prepare the MVID NDA clinical package by the end of 2026 for submission in Q2 2027

Source ACCESSWIRE +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →